胰岛素治疗对糖尿病大鼠骨骼肌内脂肪含量和CPTI-β基因表达的影响

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (9): 1065-1068.

胰岛素治疗对糖尿病大鼠骨骼肌内脂肪含量和CPTI-β基因表达的影响

吴迁, 陈璐璐, 王保平, 魏翠凤, 周慜, 李燕

华中科技大学同济医学院附属协和医院内分泌科, 武汉 430022, 湖北

收稿日期:2006-05-22 修回日期:2006-06-09 出版日期:2006-09-26 发布日期:2020-11-05
通讯作者: 陈璐璐, 医学博士, 博士生导师, 研究方向:内分泌及代谢疾病。Tel:027-85726082 　E-mail:cheriachen@sohu.com
作者简介:吴迁, 女, 硕士研究生, 研究方向:糖尿病及其慢性并发症的防治。Tel:13554302346 E-mail:wuqian200300@yahoo.com.cn

Effects of insulin treatment on content of intramyocellular triglyceride and expression of CPTI-βgene in skeletal muscle of diabetic mellitus rats

WU Qian, CHEN Lu-lu, WANG Bao-ping, WEI Cui-feng, ZHOU Min, LI Yan

Department of Endocrinology, Union Hospital of Tongji Medical College of Huazhong University of Science &Technology,Wuhan 430022 , Hubei , China

Received:2006-05-22 Revised:2006-06-09 Online:2006-09-26 Published:2020-11-05

摘要/Abstract

摘要： 目的观察胰岛素治疗对糖尿病(DM) 大鼠骨骼肌内甘油三酯(TGm) 含量和肉碱-软酯酰转移酶I-β(CPTI-β) 基因表达的影响。方法 DM 大鼠随机分为DM 高脂饮食组(DH, n =10) 和DM 高脂饮食胰岛素治疗组(DHI, n =10) , 正常Wistar 大鼠作为正常饮食对照组(NC, n =10) 。10 周后检测空腹血浆葡萄糖(FPG) 、胰岛素(FPI) 、游离脂肪酸(FFAs) 、甘油三酯(TG) 和TGm, 并根据FPG 和FPI 计算HOMA2-IR。RT-PCR 法检测骨骼肌CPTI-β基因表达水平。结果 DH 组的HOMA2-IR、TG 、FFAs 及TGm 均较NC组明显增加(p<0.01) , CPTI-β表达减少(p<0.01) 。与DH 组相比, DHI 组胰岛素抵抗减轻(p<0.05) , FFAs 明显降低(p<0.01) , 但TG 未降低(P>0.05) , 且TGm 含量进一步增加(p<0.01) , 但CPTI-β表达水平明显增加(p<0.01) 。结论 DM 大鼠TGm 含量增加并伴有CPTI-β表达降低, 胰岛素虽然能增加TGm, 但可以增加CPTI-β表达, 从而可能改善骨骼肌中的脂肪代谢。

关键词: 糖尿病, 胰岛素, 甘油三酯, 肉碱-软脂酰转移酶I-β, 骨骼肌

Abstract: AIM: To study the effect of insulin administration on the content of triglyceride and the expression of carnitine palmitoyl transferase I-β(CPTI-β) gene in skeletal muscle of diabetic mellitus (DM) rats. METHEDS: Wistar rats were randomly divided into normal control group(NC, n =10) , diabetes with high fat diet (DH, n =10) , and diabetes with high fat diet plus insulin therapy (DHI, n =10).The fasting plasma glucose(FPG) , insulin (FPI) , free fatty acids (FFAs) ,triglyceride (TG) and the TGm (intramyocellular triglyceride) and the expression of CPTI-βgene in skeletal muscle were measured.HOMA2-IR was computed on the basis of FPI and FPG.RESULTES: Compared with NC group, HOMA2-IR, TG and FFAs levels in the plasma and TGm contents of DH groupwere significantly higher (p<0.01) , and the expression of CPTI-βgene was decreased (p<0.01).Compared with DH group, insulin administration didn't normalize TG (p>0.05) , but FFAs were decreased (p<0.01) , and TGm were increased (p<0.01) , although it improved insulin sensitivity of DHI group(p<0.05) , and the expression of CPTI-βwere increased (p<0.01).CONCLUSION: TG is accumulated in the skeletal muscle of DM rats, and the expression of CPTI-βis decreased, too.Insulin administration is able to up-regulate CPTI-βtranscription, although it can increase the content of TGm as well.This phenomenon suggests insulin can ameliorate triglyceride metabolize in the DM rats.

Key words: diabetes mellitus, insulin, triglyceride, carnitine palmitoyl transferase I-β, skeletal muscle

中图分类号:

吴迁, 陈璐璐, 王保平, 魏翠凤, 周慜, 李燕. 胰岛素治疗对糖尿病大鼠骨骼肌内脂肪含量和CPTI-β基因表达的影响[J]. 中国临床药理学与治疗学, 2006, 11(9): 1065-1068.

WU Qian, CHEN Lu-lu, WANG Bao-ping, WEI Cui-feng, ZHOU Min, LI Yan. Effects of insulin treatment on content of intramyocellular triglyceride and expression of CPTI-βgene in skeletal muscle of diabetic mellitus rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(9): 1065-1068.

参考文献

1 Frayn KN.The glucose-fatty acid cycle:a physiological perspective[J].Biochem Soc Trans, 2003;31:1115-9
2 McGarry JD.Dysregulation of Fatty AcidMetabolism in the Eti-ology of Type 2 Diabetes[J].Diabetes, 2002;51:7-18
3 Goodpaster BH, Wolf D.Skeletal muscle lipid accumulation in obesity, insulin resistance, and type 2 diabetes[J].Pediatric Diabetes, 2004;5:219-26
4 Kelley DE, Simoneau JA.Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus[J].J Clin Invest, 1994;94:2349-56
5 Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG,Gadbois TM, et al.A new rat model of type 2 diabetes:the fat-fed, streptozotocin-treated rat[J].Metabolism, 2000;49:1390-94
6 Kriketos AD, Furler SM, Khee GS, Poynten AM, Chisholm DJ, Campbell LV.Multiple indexes of lipid availability are independently related to whole-body insulin action in healthy humans[J].J Clin Endocrinol Metab, 2003;88:793-8
7 Ye JM, Doyle PJ, IglesiasMA, Watson DG, Cooney GJ, Kraegen EW.Peroxisome proliferators-activated receptor (PPAR)-αactivation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats:comparison with PPAR-γactivation[J].Diabetes,2001;50:411-7
8 Krssak M, Petersen KF, Dresner A, Dipietro L, Vogel SM,Rothman DL, et al.Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans:a 1H NMR spectroscopy study[J].Diabetologia, 1999;42:113-6
9 Yu CL, Chen Y, Cline GW, Zhang DY, ZongHH, Wang YL,et al.Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-Kinase activity in muscle[J].J Biol Chem, 2002;277:50230-6
10 Summers SA, Garza LA, Zhou HL, Birnbaum MJ.Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide[J].Mol Cell Biol, 1998;18:5457-64
11 王咏波, 陈璐璐, 周敏心, 王保平.胰岛素治疗对2 型糖尿病大鼠肝脂质含量及胰岛素抵抗的影响[J].中华肝脏病杂志, 2005;l3:451-4
12 Anderwald C, Bernroider E, Krssak M, Stingl H, Brehm A,Bischof MG, et al.Effects of Insulin Treatment in Type 2 Diabetic Patients on Intracellular Lipid Content in Liver and SkeletalMuscle[J].Diabetes, 2002;51:3025-32
13 Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF,Ursich MJ, et al.Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects[J].Diabetes, 1999;48:1836-41
14 Somwar R, PerreaultM, Kapur S, Taha C, Sweeney G, Ramlal T, et al.Activation of p38 mitogen-activated protein Kinase αand βby insulin and contraction in rat skeletal muscle potential role in the stimulation of glucose transport[J].Diabetes,2000;49:1794-800
15 Puigserver P, Spiegelman BM.Peroxisome proliferator-activated receptor-γcoactivator 1α(PGC-1α):transcriptional coactivatorand metabolic regulator[J].Endocrine Reviews, 2003;24:78-90

[1]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[2]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[3]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[4]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[5]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[6]	张雪娇, 刘洁婷, 李鲁新, 陈培剑, 丁明璐, 孙梦伟, 初彦辉, 张珍. 达格列净对1型糖尿病小鼠心肌损伤的影响及机制研究[J]. 中国临床药理学与治疗学, 2023, 28(3): 257-265.
[7]	白佳, 杨虹, 李玲玲, 张洋洋, 杨莹, 吕海宏. 维生素D通过线粒体/自噬途径影响糖尿病神经病变机制的研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 214-219.
[8]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[9]	杜小雨, 李宇蒙, 吴惠珍, 邱博. 多格列艾汀治疗2型糖尿病的药理作用和临床评价[J]. 中国临床药理学与治疗学, 2023, 28(10): 1177-1183.
[10]	汤紫照, 聂方钦, 晏欣, 符阳霞, 黄珺, 汪霞, 郭韧. Atglistatin对棕榈酸诱导的血管平滑肌细胞增殖及ATGL表达的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 29-35.
[11]	蔡静, 潘斌晶, 刘靖芳. 降糖药物与肌肉减少症关系的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 101-108.
[12]	杨丽, 柏虎虎, 贺沙沙, 金月, 刘成松. TRPM3的酪氨酸磷酸化参与糖尿病诱发的热痛觉过敏[J]. 中国临床药理学与治疗学, 2022, 27(9): 971-976.
[13]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.
[14]	付勇芳, 郭怡洵, 王晶, 李文雄, 张岩. 基于衰老视角评析肌少症实验药理模型的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 892-898.
[15]	卢森林, 刘欣元, 王吉莉, 黄晓飞. 病毒载体介导的基因治疗在2型糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 800-807.